1. Home
  2. JGH vs PRQR Comparison

JGH vs PRQR Comparison

Compare JGH & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JGH
  • PRQR
  • Stock Information
  • Founded
  • JGH 2014
  • PRQR 2012
  • Country
  • JGH United States
  • PRQR Netherlands
  • Employees
  • JGH N/A
  • PRQR N/A
  • Industry
  • JGH Investment Managers
  • PRQR Biotechnology: Pharmaceutical Preparations
  • Sector
  • JGH Finance
  • PRQR Health Care
  • Exchange
  • JGH Nasdaq
  • PRQR Nasdaq
  • Market Cap
  • JGH 292.3M
  • PRQR 179.1M
  • IPO Year
  • JGH N/A
  • PRQR 2014
  • Fundamental
  • Price
  • JGH $13.07
  • PRQR $2.45
  • Analyst Decision
  • JGH
  • PRQR Strong Buy
  • Analyst Count
  • JGH 0
  • PRQR 8
  • Target Price
  • JGH N/A
  • PRQR $8.88
  • AVG Volume (30 Days)
  • JGH 73.9K
  • PRQR 365.1K
  • Earning Date
  • JGH 01-01-0001
  • PRQR 08-07-2025
  • Dividend Yield
  • JGH 9.85%
  • PRQR N/A
  • EPS Growth
  • JGH N/A
  • PRQR N/A
  • EPS
  • JGH N/A
  • PRQR N/A
  • Revenue
  • JGH N/A
  • PRQR $21,212,711.00
  • Revenue This Year
  • JGH N/A
  • PRQR N/A
  • Revenue Next Year
  • JGH N/A
  • PRQR N/A
  • P/E Ratio
  • JGH N/A
  • PRQR N/A
  • Revenue Growth
  • JGH N/A
  • PRQR 85.91
  • 52 Week Low
  • JGH $10.36
  • PRQR $1.07
  • 52 Week High
  • JGH $12.85
  • PRQR $4.62
  • Technical
  • Relative Strength Index (RSI)
  • JGH 71.02
  • PRQR 71.45
  • Support Level
  • JGH $13.03
  • PRQR $2.10
  • Resistance Level
  • JGH $13.23
  • PRQR $2.42
  • Average True Range (ATR)
  • JGH 0.09
  • PRQR 0.14
  • MACD
  • JGH 0.03
  • PRQR 0.02
  • Stochastic Oscillator
  • JGH 85.71
  • PRQR 73.17

About JGH Nuveen Global High Income Fund of Beneficial Interest

Nuveen Global High Income Fund operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of current income. Its securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.

About PRQR ProQR Therapeutics N.V.

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.

Share on Social Networks: